Press Releases Archives - EvolveImmune

10th November 2022

EvolveImmune Therapeutics Reports Preclinical Data Highlighting Deep and Durable Anti-Tumor Efficacy with EV-104 in Presentation at 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

27th October 2022

EvolveImmune Therapeutics Presents Promising Preclinical Data from Novel Costimulatory T Cell Engager Platform at American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy

19th October 2022

EvolveImmune Therapeutics to Present New Preclinical Data from Novel Costimulatory T Cell Engager Platform at Upcoming Scientific Conferences

7th July 2022

EvolveImmune Therapeutics Appoints Jay Fine, Ph.D., as President of Research and Development